Clinical Trial Update: Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) [Phase 1, Phase 2]

View source ↗

Summary

This is a Phase 1/2 clinical trial update evaluating immune and targeted combination therapies in second-line plus renal cell carcinoma (MK-3475-03B/KEYMAKER-U0…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Renal Cell | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING